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aBStraCt 
Introduction: The leading cause of hospital-acquired infections are the pathogens named by the acronym ESKAPE, which are the initials for 
the following bacterial: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,  Acinetobacter baumanni, Pseudomonas 
aeruginosa and Enterobacter spp., which have high resistance rates by escaping the action of the antimicrobial. Objective: To trace the 
antimicrobial susceptibility profile of the ESKAPE pathogens in a primary public hospital in the Federal District, Brazil. Methods: A cross-
sectional, retrospective and descriptive study was conducted by analyzing the corresponding data from January 2010 to December 2015 of 
samples considered positive to ESKAPE pathogens in order to generate an antimicrobial susceptibility profile. Results: Analyzing the Gram-
positive bacteria, almost 80% of E. faecium strains were vancomycin-resistant enterococci (VRE) and almost 40% of S. aureus strains were 
methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA). It was observed that gram-negative strains (the ESKAPE group) examined 
in this study have a higher resistance rate to carbapenems than in other studies. In the molecular analysis, four Klebsiella pneumoniae 
strains were positive to bla
KPC 
gene, three strains to bla
NDM
 and one Acinetobacter baumanni strain was positive to bla
OXA-23
 gene. 
Conclusion: Studies such as this should be performed periodically in order to evaluate the bacterial susceptibility profile. They demonstrate 
the importance of implementing strategies to prevent hospital-acquired infections, as well as greater antibiotic prescribing control. 
Key words: microbial sensitivity tests; genes; bacteria.
introDuCtion
Bacteria may be intrinsically resistant to an antimicrobial, when 
it is an inherent characteristic of a species, related to chromosomal 
genes. Furthermore, they may acquire resistance to certain 
antimicrobials through chromosomal mutations or horizontal 
gene transfer by three mechanisms: 1) bacteriophage-mediated 
transduction; 2) transformation by chromatin incorporation of 
chromosomes, plasmids and deoxyribonucleic acid (DNA) from dead 
organisms; and 3) conjugation through plasmids and conjugative 
transposons(1, 2). These transfers may occur in water, soil, food, and 
the digestive system of animals and humans(3).
These resistances hindering patients’ treatment, since the use 
of broad spectrum antimicrobials is required, but the development 
and approval of new drugs grow at a much slower rate than the 
emergence of bacterial resistance. Bacterial resistance mechanisms 
usually occur two or three years after the introduction of a new 
antimicrobial into therapy(4)  and a drug of this type can take 
12 to 22 years to be available in the market(5). This reduces the 
effectiveness of the antimicrobial treatment, making it difficult 
and costly, which can increase the length of hospital stay of 
infected patients and often leading to their death(6-8). Bacteria 
from the ESKAPE group (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumanni, 
Pseudomonas aeruginosa and Enterobacter spp.) are the main 
causes of hospital-acquired infections in the United States and 
they are able to escape from the antimicrobial actions due to the 
resistance profile(9). 
It is necessary that studies trace periodically the bacterial 
resistance profile, to contribute for both local and global 
epidemiological data. These data assist in therapeutic 















locally, adding it to the clinical effectiveness and cost of the 
antimicrobial. The present study aims to evaluate the susceptibility 
profile of ESKAPE pathogens in a primary hospital of the public 




Characterization of the study
The present study is considered cross-sectional, retrospective 
and descriptive, in which were analyzed the data from 
antimicrobial susceptibility tests performed in the microbiology 
sector of the clinical analysis laboratory of a hospital in the 
public network of Brasília, Brazil, in the period from January 
2010 to December 2015. The hospital analyzed is a primary 
hospital, and does not have an intensive care unit. This study 
was approved by the Research Ethics Committee of the Faculty 




Using WHONET 5.6 software, 2,527 samples were analyzed, 
among which 577 were positive to the ESKAPE group pathogens. 
Data such as age, sex and type of sample were considered. The 
minimum inhibitory concentration (MIC) used to trace 
the susceptibility profile was interpreted from the cut-off points 
determined by the Clinical & Laboratory Standards Institute 
(CLSI) 2015. 
WHONET is a program developed for the analysis and 
monitoring of microbiological data, especially for antimicrobial 
susceptibility test. It was developed in 1989 by the Collaborating 
Center for Surveillance of Antimicrobial Resistance of the 
World Health Organization (WHO), helping to understand 
epidemiological data for antimicrobial choice and outbreak 
detection(10). It is a free program, used in more than 90 countries, 
and available in more than 20 languages, including Portuguese.
 
Bacterial isolates
The resistance genes were investigated in eight samples that 
were sent to the Central Public Health Laboratory of the Federal 
District [Laboratório Central de Saúde Pública do Distrito 
Federal (LACEN/DF)] for genetic identification, of which 
seven Klebsiella pneumoniae strains and one Acinetobacter 
baumannii. The criterion for sending the strains of these 
enterobacteria used by the laboratory of clinical analyzes of the 
public health network was the carbapenem-resistance profile 
and also the modified Hodge test or enzymatic blockade test with 
positive ethylenediamine tetraacetic acid (EDTA)(11, 12).
 
Molecular detection of genes by polymerase chain 
reaction (PCR)









 were investigated, since they were the most prevalent in 
carbapenem-resistant enterobacteria, and the bla
OXA-23,
 gene 
in carbapenem-resistant Acinetobacter baumannii in Brazil(13, 14). 
For this purpose, we used the primers indicated in Table 1.
taBLE 1 − Primers used
Primers Sequence Amplicon size (PB)
NDM F 5’ GGTTTGGCGATCTGGTTTTC
512
NDM R 5’ GGCCTTGCTGTCCTTGATC
KPC F 5’ TGTCACTGTATCGCCGTC
1011
KPC R 5’ CTCAGTGCTCTACAGAAAACC
VIM F 5’ GATGGTGTTTGGTCGCATATC
332






OXA-23 R 5’ ATTTCTGACCGCATTTCCAT
NDM: New Delhi metalo-betalactamase; F: forward; R: reverse; KPC: Klebsiella pneumoniae 
carbapenemase; OXA: oxacilinase.
Source: Faria Junior et al. (2016)(15) and Woodford N et al. (2006)(16).
The reactions were subjected to the temperature cycles 
programming of 2 minutes at 94ºC, followed by 40 cycles, 
denaturation at 94ºC for 45 seconds, annealing at 58ºC for 45 
seconds and extension at 72ºC for 1 minute. The PCR was concluded 
with the extension cycle at 72ºC for 2 minutes. The PCR products, 
15 μl, were visualized on 2% agarose gel electrophoresis, prepared 
in 1× tris-acetate-EDTA (TAE) buffer, followed by gel staining in 
ethidium bromide solution; the amplified fragments were observed 




When analyzing the samples regarding age and gender, it was 
observed that 52% of the patients are male and 48.2% correspond 
to the age group of 60 years or older (Table 2). 
From 577 samples, the most prevalent microorganism was 
Klebsiella pneumoniae (41%), followed by Staphylococcus aureus 
(22%), Pseudomonas aeruginosa (14%), Enterobacter spp. (11%), 
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Acinetobacter baumannii (8%) and Enterococcus faecium (4%). 
The isolates analyzed were obtained mainly from urine (46%), 
retal swab (19%), nasal swab (11%) and blood (8%). In urine and 
rectal swab, the microorganism most commonly found Klebsiella 
pneumoniae, and in nasal swab and blood, was Staphylococcus 
aureus (Table 3).
When analyzing gram-positive bacteria, about 80% of the 
Enterococcus faecium strains were resistant to vancomycin – 
vancomycin-resistant enterococci (VRE) –, and also had a higher 
resistance to erythromycin (95.8%), followed by ciprofloxacin 
(91.7%), ampicillin (91.7%) and penicillin G (91.7%), and 
increased sensitivity to linezolid (87.5%) and daptomycin (83.3%) 
(Figure). 
From the Staphylococcus aureus, 40% strains presented 
resistance to oxacillin (MRSA), 96.9% were resistant to 
penicillin G, 75.8% to erythromycin and 63.3% to ciproflxacin 
and levoflxacin. S. aureus strains resistant to linezolid (3.9%), 
daptomycin (4.7%) and vancomycin (2.3%) were also found.
When analyzing the susceptibility profile for Klebsiella 
pneumoniae, it was possible to observe that this strain presented 
the highest resistance rates to the following antimicrobials: 
aztreonam, cefepime and cefotaxime (75.2%) and ertapenem 
(69.7%); and the lowest rate of resistance was 2.6% to amikacin.
Acinetobacter baumannii presented the most worrying 
susceptibility profile, presenting a resistance frequency of 
100% to imipenem; 91.1% to ciprofloxacin, ceftazidime and 
cefotaxime; 88.8% to cefepime; 86% to meropenem and 82.2% 
to levofloxacin. 
The highest resistance rates to Pseudomonas aeruginosa 
were 54.3% to ciprofloxacin, 53.1% to levofloxacin and 
imipenem, and 47% to norfloxacin. While that to Enterobacter 
spp. 96% were resistant to cephalothin; 87.5% to amoxicillin/
clavulanic acid; 79.2% to cefoxitin; 78.5% to ampicillin; and 
73.9% to cefotaxime. 
In molecular analysis, the blaKPC gene was found in four 
Klebsiella pneumonieae strains, which were one in rectal 
swab specimens and three in urine samples; the bla
NDM
 gene 
was found in three Klebsiella pneumonieae positive retal swab 
samples, while the bla
OXA-23
 gene was found in one Acinetobacter 




The incidence of VRE among the E. faecium is worrisome, 
since these strains have become a worldwide problem due to 
infections caused in association with hospital morbidity and 
mortality(17), as well as S. aureus strain resistant to linezolid 
and daptomycin, these antimicrobials are considered as the 
final option for the treatment of infections caused by MRSA(18).
Compared to a study conducted in Latin America (Argentina, 
Brazil, Chile and Mexico) from 2008 to 2010, the susceptibility 
profile analyzed in this study showed a greater resistance to 
imipenem and meropenem, while in Latin America they showed 
resistance around 6% to these antimicrobials and 36% to cefepime. 
However, in this study the resistance found to amikacin and 
gentamicin was lower than that found in Latin America, 7.8% 
and 33%, respectively(19). When comparing the results obtained 







Enterococcos faecium 3 20 - 1 - 24
Staphylococcus aureus 17 - 63 29 19 128
Klebsiella pneumoniae 165 54 - 5 10 234
Acinetobacter baumannii 8 16 1 5 15 45
Pseudomonas aeruginosa 30 9 - 3 39 81
Enterobacter spp. 46 9 - 2 8 65
Total 269 108 64 45 91 577
taBLE 2 − Age group by sex of positive samples between 2010 and 2015
Age group (years) Total % Female % Male %
0-9 40 6.9 20 7.2 20 6.7
10-19 16 2.8 16 5.8 0 0
20-59 206 35.7 103 37.1 103 34.4
≥ 60 278 48.2 124 44.6 154 51.5
Not reported 37 6.4 15 5.4 22 7.4
Total 577 100 278 100 299 100
figurE − Susceptibility profile of Enterococcus faecium
The red bar represents the percentage of antimicrobial resistance, the orange bar indicates 
the intermediate profile and the green bar represents the percentage of sensitivity.
 Vancomycin    79.2     
 Tetracycline   37.5 
 Penicillin G      91.7
 Linezolid  8.3
 Levofloxacin     87.5
 Erythromycin      95.8
 Daptomycin  16.7
 Ciprofloxacin     91.7
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with a study conducted in 2011 in a university hospital in 
Londrina, Paraná, Brazil, the profile found in the present study 
demonstrated a higher frequency of resistance compared to the 
following antimicrobials: ertapenem (40%) and cefotaxime, 
cefepime and aztreonam (60%)(20).
Acinetobacter baumannii showed the most worrying 
susceptibility profile, since this bacterium are easy to develop 
resistance. In the 1990s, most strains were sensitive to quinolones 
and carbapenems, and several outbreaks of multidrug resistant 
strains have been reported in recent years(21). The decrease in 
susceptibility to carbapenems can be observed when comparing 
two studies conducted by the Sentry Antimicrobial Surveillance 
Program in Brazil in 2001 and 2010, especially imipenem, which 
reduced from 97.8% to 27%, and to meropenem, which previously 
was 96.7% and today is 27.3%(19, 22). In a study that analyzed 
only the Gram-negative pathogens of the ESKAPE group in the 
Latin American countries A. baumanni was the pathogen with 
the highest resistance rate to amikacin, cefepime, ceftazidime, 
imipenem and levofloxacin(23).
When comparing Pseudomonas aeruginosa with a study 
carried out in Bahia, by Assis et al. (2012)(24), 66% of the strains 
were resistant to levofloxacin and 51%, to amikacin, that is, 
they showed greater resistance. However, this study showed 
less resistance to meropenem (34%)(24). Comparing the results 
obtained with another study conducted in Latin America 
(Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, 
Guatemala, Mexico, Panama, Peru and Venezuela), it was 
possible to observe a greater resistance to imipenem (44.9%) 
and to levofloxacine (38.2%), and a similar resistance rate to 
meropenem (38.4%) and Amikacin (20.5%)(25).
Regarding Enterobacter spp., this study presented a greater 
resistance to amoxicillin/clavulanic acid than the study carried 
out in Rondônia, Brazil, in which the resistance rate was 
66.7%(6).
Klebsiella pneumoniae carbapenemase (KPC) strain, New 
Delhi metalo-betalactamase (NDM-1) and oxacilinase-23 (OXA-
23) are carbapenemases. KPC belongs to Amber class A and 
NDM-1, to Amber class B [metalo-β-lactamase (MBL)(26, 27)]. 
Class A hydrolyzes penicillins, cephalosporins, carbapenems and 
aztreonam, but this hydrolysis is inhibited in vitro by the 
clavulanic acid and tazobactam. However, class B hydrolyzes all 
beta-lactams mentioned above, with the exception of aztreonam, 
and does not have its activity inhibited by beta-lactam inhibitors, 
since its hydrolysis depends on the interaction of betalactam with 
zinc ions at its catalytic site; its activity is inhibited in vitro by 
EDTA(14). Oxacillinases are class D, and in Brazil OXA-23 stands 
out(13, 28).
These genes have already been described in Brazil, and the 
first report of the presence of KPC in brazil was in 2009, after 
the discovery of the gene in strains isolated from a patient in an 
intensive care unit at a tertiary hospital in Recife, Brazil(29). The 
first strain containing NDM-encoding gene in Brazil was isolated 
in Rio Grande do Sul and later a strain with this gene was also 
found in the Federal District(15, 30). The first description of OXA-23 
in Brazil was established from A. baumannii isolates found in 
1999 in two tertiary hospitals in Curitiba, Paraná, Brazil(31). 
It is important to emphasize that the hospital studied is 
considered small and, although only few strains with resistance 
profile have been found, this is still worrying. This resistance is 
not specific to this hospital, since most of the patients come from 
other hospitals in the public health network of the Federal District, 




Brazil took an important step towards the control of multi-drug 
resistant strains by prohibiting the sale of antimicrobials without 
prescription through the RDC 44/2010, which was replaced by 
the RDC 20/2011 of the National Sanitary Surveillance Agency 
[Agência Nacional de Vigilância Sanitária (Anvisa)], reducing 
its irrational use. However, many practitioners still prescribe 
antimicrobials without any need, or prescribe broad spectrum 
antimicrobials when the first-choice antimicrobials are effective. 
Thus, this work demonstrates important data that reflect an 
increase in the prevalence of MDR strains in hospitalized 
patients of the Federal District, Brazil.
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rESuMo 
Introdução: Os principais patógenos causadores de infecções nosocomiais foram resumidos pela sigla ESKAPE, que são as iniciais 
das seguintes bactérias: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas 
aeruginosa e Enterobacter spp., as quais possuem altas taxas de resistência por conseguirem escapar das ações dos antimicrobianos. 
Objetivo: Traçar o perfil de suscetibilidade antimicrobiana do grupo ESKAPE em um hospital primário da rede pública do Distrito 
Federal, Brasil. Métodos: Foi realizado um estudo transversal, retrospectivo e descritivo, analisando os dados correspondentes de 
janeiro de 2010 a dezembro de 2015 para as amostras consideradas positivas para o grupo ESKAPE, com o intuito de gerar um 
perfil de sensibilidade aos antimicrobianos. Resultados: Ao analisar bactérias Gram positivas, quase 80% das cepas de Enterococcus 
faecium foram resistentes à vancomicina (VRE) e cerca de 40% das cepas de Staphylococcus aureus, resistentes à oxacilina (MRSA). 
Nas bactérias do grupo ESKAPE, observaram-se cepas com uma taxa de resistência maior aos carbapenens do que em outros 
estudos. Ao realizar uma análise molecular, quatro cepas de Klebsiella pneumoniae foram positivas para o gene bla
KPC
 e três, para 
o bla
NDM
; uma de Acinetobacter baumanni foi positiva para o gene bla
OXA-23
. Conclusão: Estudos como este devem ser realizados 
periodicamente de modo a avaliar o perfil de suscetibilidade das bactérias. Eles demonstram a importância do uso de estratégias 
para evitar infecções nosocomiais, bem como um maior controle na prescrição de antimicrobianos.
Unitermos: testes de sensibilidade microbiana; genes; bactérias.
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